Cargando…

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial

OBJECTIVES: Recent studies suggest that implementation of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) leads to higher inflammatory activity in seronegative compared with seropositive patients at time...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordberg, Lena Bugge, Lillegraven, Siri, Aga, Anna-Birgitte, Sexton, Joseph, Olsen, Inge Christoffer, Lie, Elisabeth, Berner Hammer, Hilde, Uhlig, Till, van der Heijde, Desirée, Kvien, Tore K, Haavardsholm, Espen A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269640/
https://www.ncbi.nlm.nih.gov/pubmed/30564452
http://dx.doi.org/10.1136/rmdopen-2018-000752
_version_ 1783376515534159872
author Nordberg, Lena Bugge
Lillegraven, Siri
Aga, Anna-Birgitte
Sexton, Joseph
Olsen, Inge Christoffer
Lie, Elisabeth
Berner Hammer, Hilde
Uhlig, Till
van der Heijde, Desirée
Kvien, Tore K
Haavardsholm, Espen A
author_facet Nordberg, Lena Bugge
Lillegraven, Siri
Aga, Anna-Birgitte
Sexton, Joseph
Olsen, Inge Christoffer
Lie, Elisabeth
Berner Hammer, Hilde
Uhlig, Till
van der Heijde, Desirée
Kvien, Tore K
Haavardsholm, Espen A
author_sort Nordberg, Lena Bugge
collection PubMed
description OBJECTIVES: Recent studies suggest that implementation of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) leads to higher inflammatory activity in seronegative compared with seropositive patients at time of diagnosis. Our aim was to compare the disease course in seronegative and seropositive patients classified according to the 2010 criteria. METHODS: DMARD-naïve patients with RA fulfilling the 2010 criteria were included in the treat-to-target ARCTIC trial and followed for 24 months. We stratified patients as seropositive (rheumatoid factor (RF)+, anticitrullinated protein antibodies (ACPA)+ or both) or seronegative (RF– and ACPA–) and compared disease activity, radiographic progression, treatment response and remission rates across groups. RESULTS: 230 patients were included with mean (SD) age 51.4 (13.7) years, and 61% were female. 34 patients (15%) were seronegative. At 24  months, disease activity measures, radiographic progression and remission rates were similar between groups, despite more inflammatory activity in seronegative patients at baseline. Treatment response was slower in seronegative compared with seropositive patients. The groups received similar treatment. CONCLUSION: Our findings suggest that among patients with RA classified according to the 2010 ACR/EULAR criteria, seronegative patients respond well to modern treatment strategies. However, treatment response was somewhat slower in seronegative patients and radiographic progression was similar in seronegative and seropositive patients. Our results indicate that seronegative RA is not a mild form of the disease and requires intensive treat-to-target therapy similar to treatment of seropositive RA.
format Online
Article
Text
id pubmed-6269640
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-62696402018-12-18 Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial Nordberg, Lena Bugge Lillegraven, Siri Aga, Anna-Birgitte Sexton, Joseph Olsen, Inge Christoffer Lie, Elisabeth Berner Hammer, Hilde Uhlig, Till van der Heijde, Desirée Kvien, Tore K Haavardsholm, Espen A RMD Open Rheumatoid Arthritis OBJECTIVES: Recent studies suggest that implementation of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) leads to higher inflammatory activity in seronegative compared with seropositive patients at time of diagnosis. Our aim was to compare the disease course in seronegative and seropositive patients classified according to the 2010 criteria. METHODS: DMARD-naïve patients with RA fulfilling the 2010 criteria were included in the treat-to-target ARCTIC trial and followed for 24 months. We stratified patients as seropositive (rheumatoid factor (RF)+, anticitrullinated protein antibodies (ACPA)+ or both) or seronegative (RF– and ACPA–) and compared disease activity, radiographic progression, treatment response and remission rates across groups. RESULTS: 230 patients were included with mean (SD) age 51.4 (13.7) years, and 61% were female. 34 patients (15%) were seronegative. At 24  months, disease activity measures, radiographic progression and remission rates were similar between groups, despite more inflammatory activity in seronegative patients at baseline. Treatment response was slower in seronegative compared with seropositive patients. The groups received similar treatment. CONCLUSION: Our findings suggest that among patients with RA classified according to the 2010 ACR/EULAR criteria, seronegative patients respond well to modern treatment strategies. However, treatment response was somewhat slower in seronegative patients and radiographic progression was similar in seronegative and seropositive patients. Our results indicate that seronegative RA is not a mild form of the disease and requires intensive treat-to-target therapy similar to treatment of seropositive RA. BMJ Publishing Group 2018-11-16 /pmc/articles/PMC6269640/ /pubmed/30564452 http://dx.doi.org/10.1136/rmdopen-2018-000752 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Rheumatoid Arthritis
Nordberg, Lena Bugge
Lillegraven, Siri
Aga, Anna-Birgitte
Sexton, Joseph
Olsen, Inge Christoffer
Lie, Elisabeth
Berner Hammer, Hilde
Uhlig, Till
van der Heijde, Desirée
Kvien, Tore K
Haavardsholm, Espen A
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
title Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
title_full Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
title_fullStr Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
title_full_unstemmed Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
title_short Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
title_sort comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 acr/eular classification criteria in a treat-to-target setting: 2-year data from the arctic trial
topic Rheumatoid Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269640/
https://www.ncbi.nlm.nih.gov/pubmed/30564452
http://dx.doi.org/10.1136/rmdopen-2018-000752
work_keys_str_mv AT nordberglenabugge comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT lillegravensiri comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT agaannabirgitte comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT sextonjoseph comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT olseningechristoffer comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT lieelisabeth comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT bernerhammerhilde comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT uhligtill comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT vanderheijdedesiree comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT kvientorek comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial
AT haavardsholmespena comparingthediseasecourseofpatientswithseronegativeandseropositiverheumatoidarthritisfulfillingthe2010acreularclassificationcriteriainatreattotargetsetting2yeardatafromthearctictrial